Trillium Therapeutics (NASDAQ:TRIL) Downgraded by HC Wainwright to Neutral

HC Wainwright lowered shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) from a buy rating to a neutral rating in a research note released on Monday morning, BenzingaRatingsTable reports.

Other equities analysts have also recently issued reports about the company. Cowen restated a buy rating on shares of Trillium Therapeutics in a report on Thursday, August 15th. Zacks Investment Research upgraded Trillium Therapeutics from a hold rating to a buy rating and set a $0.25 price target on the stock in a report on Saturday, August 17th.

Trillium Therapeutics stock opened at $0.29 on Monday. The stock has a market capitalization of $7.83 million, a price-to-earnings ratio of -0.12 and a beta of 2.20. Trillium Therapeutics has a 52-week low of $0.24 and a 52-week high of $6.75. The stock’s 50 day moving average price is $0.33 and its two-hundred day moving average price is $0.58.

Several institutional investors have recently bought and sold shares of TRIL. Jane Street Group LLC bought a new position in shares of Trillium Therapeutics during the 4th quarter worth approximately $43,000. Geode Capital Management LLC boosted its holdings in shares of Trillium Therapeutics by 164.0% during the 4th quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock worth $45,000 after buying an additional 16,541 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Trillium Therapeutics during the 1st quarter worth approximately $73,000. Morgan Stanley boosted its holdings in shares of Trillium Therapeutics by 35.8% during the 2nd quarter. Morgan Stanley now owns 1,045,698 shares of the biotechnology company’s stock worth $343,000 after buying an additional 275,800 shares in the last quarter. Finally, NEA Management Company LLC boosted its holdings in shares of Trillium Therapeutics by 68.0% during the 1st quarter. NEA Management Company LLC now owns 2,100,000 shares of the biotechnology company’s stock worth $1,386,000 after buying an additional 850,000 shares in the last quarter. Hedge funds and other institutional investors own 24.63% of the company’s stock.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Further Reading: How accurate is the Rule of 72?

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.